Key result
Each 1-mm increment in epicardial fat tissue thickness was associated with a two-fold increased risk of metabolic syndrome in COPD patients (OR 2.08; 95% CI 1.18-3.68; p=0.011).
Why the study?
Does epicardial fat tissue thickness predict metabolic syndrome in patients with chronic obstructive pulmonary disease?
Case-Control (n=166)
No
Does epicardial fat tissue thickness predict metabolic syndrome in patients with chronic obstructive pulmonary disease?
Epicardial fat tissue thickness is a valuable, non-invasive parameter for predicting increased risk of metabolic syndrome in COPD patients.
May support epicardial fat thickness as a predictor of metabolic syndrome in COPD; leaves open its incremental value over conventional risk factors.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Melike Demir (2016) conducted a case-control in Chronic obstructive pulmonary disease (COPD) (n=166). Epicardial fat tissue (EFT) thickness vs. Lower EFT thickness / Healthy controls was evaluated on Risk of metabolic syndrome per 1-mm increment of EFT (OR 2.08, 95% CI 1.18-3.68, p=0.011). Each 1-mm increment in epicardial fat tissue thickness was associated with a two-fold increased risk of metabolic syndrome in COPD patients (OR 2.08; 95% CI 1.18-3.68; p=0.011).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: